Samjin Pharmaceutical

005500 · KOSPI · ₩005500 · 삼진제약

₩19,310▲ ₩150 (0.78%)End-of-day · Oct 27, 2026 · End-of-day prices.
Trade
Alert me

Valuation model · Discounted cash flow (DCF)

We use a 5-year discounted cash flow: the value of the cash the business is expected to produce, in today's money.

Fair value per share

₩24,591

vs the current price (₩19,310)

Enterprise value
₩326B
Equity value
₩328B
WACC
7.2%

Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal. This is not financial advice.

Bear / Base / Bull

Bear
₩13,793
−28.6%
Base
₩24,591
+27.3%
Bull
₩43,809
+126.9%

Bear: revenue growth 3 points lower every year, EBIT margin 2 points lower, WACC 1 point higher. Bull: the opposite.

Assumptions

Sign in to change the assumptions and see the results update. Sign in

Cycle options

Margin path

Every year uses the cycle-average margin (8.8%).

Revenue growth

  • 4.1%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (4.1% a year, annual reports), fading to 3% by year 5.

  • 3.8%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (4.1% a year, annual reports), fading to 3% by year 5.

  • 3.5%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (4.1% a year, annual reports), fading to 3% by year 5.

  • 3.3%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (4.1% a year, annual reports), fading to 3% by year 5.

  • 3%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (4.1% a year, annual reports), fading to 3% by year 5.

Business

  • 8.8%

    Operating profit as a share of revenue.

    Default: through-the-cycle average of the last 12 months and the last 5 annual reports' operating margins.

  • 27.5%

    Share of operating profit paid as corporate tax.

    Default: Korea's top corporate tax rate (25%) plus 10% local income tax.

  • 3%

    The non-cash cost of wearing out equipment, added back to cash flow (% of revenue).

    Default: not in the statements, so a typical level.

  • 4%

    Money spent on factories, equipment, software and other long-term assets (% of revenue).

    Default: not in the statements, so a typical level.

  • 40%

    Stock and unpaid customer bills, less unpaid supplier bills, as a % of revenue. Each year's extra revenue ties up this much more cash.

    Default: working capital (current assets less cash and deposits, minus current liabilities other than borrowings) as a share of revenue, averaged over the last 3 years.

Discount rate

  • 2%

    How fast cash flows keep growing every year after year 5.

    Default: about Korea's long-run inflation plus real growth.

  • 4.03%

    Yield on Korea's 10-year government bond: the return with almost no risk.

    Default: Korea Treasury Bond 10-year yield on 2026-10-27.

  • 0.6

    How much the share moves when the market moves: 1 means just like the market.

    Default: 105 weeks of weekly returns against KOSPI (official index); raw beta 0.1, adjusted toward 1 and kept between 0.6 and 2.0.

  • 5.5%

    The extra return investors want for owning shares instead of bonds.

    Default: a typical premium for Korean shares.

  • 5.53%

    The interest rate the company would pay to borrow.

    Default: the 10-year yield plus a 1.5% credit spread.

Starting point

Revenue (TTM to H1 2026)
₩311B
Net debt (borrowings and leases − cash and deposits)
₩8B
+ Stakes and investments
₩10B
Associates, long-term financial assets and deposits (book value)
Shares
13,320,000
Share price
₩19,310
Market cap
₩257B

TTM = trailing 12 months: the last four reported quarters added together. "TTM to H1 2026" is the 12 months up to the latest quarterly or half-year report (H1 = to the end of June). Year 1 grows from there.

Past years and projection

Grey columns are reported results from the annual reports (after-tax EBIT at the model's tax rate), so you can check the growth and margin assumptions against the past. Years 1–5 are the model.

FY2023FY2024FY2025Year 1Year 2Year 3Year 4Year 5
Revenue₩292B₩308B₩309B₩324B₩336B₩348B₩360B₩371B
Growth6.6%5.6%0.3%4.1%3.8%3.5%3.3%3.0%
EBIT₩20B₩32B₩27B₩29B₩30B₩31B₩32B₩33B
EBIT margin7.0%10.3%8.7%8.8%8.8%8.8%8.8%8.8%
After-tax EBIT₩15B₩23B₩19B₩21B₩21B₩22B₩23B₩24B
+ Depreciation———₩9.7B₩10B₩10B₩11B₩11B
− Capital spending———₩13B₩13B₩14B₩14B₩15B
− Working capital₩25B₩5B₩21B₩5.1B₩4.9B₩4.7B₩4.6B₩4.3B
Free cash flow———₩12B₩13B₩14B₩15B₩16B
Discount factor———0.9330.8700.8110.7560.705
Present value———₩12B₩11B₩11B₩11B₩11B

Terminal value ₩381B, worth ₩269B today: 83% of enterprise value. It assumes spending settles at 110% of depreciation once growth slows to the terminal rate.

Cross-check: what the market has paid before

For cyclical businesses, analysts check a DCF against the multiples the stock has traded at through past cycles. Price / book is the usual anchor for them: P/E looks highest at the bottom of a cycle, when earnings are smallest, and lowest at the top. The price each band would give today:

LowTypicalHigh
Price / book (book value ₩22,430 a share)Now 0.86×₩19,1090.85×₩23,0001.03×₩32,3081.44×
Price / earnings (last 12 months: ₩1,642 a share)Now 11.8×₩9,9386.05×₩20,37412.4×₩31,60519.3×
P/E on run-rate earnings (Q2 2026 × 4: ₩1,413 a share)Now 13.7×₩8,5536.05×₩17,53412.4×₩27,19919.3×

Low, typical and high are the 10th percentile, middle and 90th percentile of month-end multiples since 2021, each against the latest report out by then, per share at today's share count; loss years and P/E above 100 are left out. Run-rate earnings are one quarter × 4, not a forecast. Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal.

Sensitivity

Fair value per share as two inputs change; the middle is the current case.

WACC ↓ · Terminal growth →1.0%1.5%2.0%2.5%3.0%
6.2%₩27,060₩28,684₩30,681₩33,203₩36,493
6.7%₩24,555₩25,806₩27,312₩29,166₩31,505
7.2%₩22,455₩23,433₩24,591₩25,984₩27,698
7.7%₩20,671₩21,445₩22,347₩23,414₩24,698
8.2%₩19,137₩19,755₩20,466₩21,294₩22,274

Now (TTM)

Market cap
₩257B
Enterprise value
₩264B
P/E
11.8×
P/B
0.9×
P/S
0.8×
EV/EBITDA
—
Dividend yield
4.1%

Over time (at each year end)

20252024202320222021
Price₩19,750₩18,070₩21,600₩25,650₩26,300
Market cap₩263B₩241B₩288B₩342B₩350B
P/E10.9×6.1×15.2×16.2×12.3×
P/B0.9×0.9×1.1×1.2×1.5×
P/S0.9×0.8×1.0×1.2×1.4×
EV/EBITDA—————
Dividend yield4.1%4.4%———

Versus similar companies

CompanyP/EP/BP/SEV/EBITDADividend yield
Samjin Pharmaceutical11.8×0.9×0.8×—4.1%
Samsung Biologics32.1×7.6×14.0×—0.0%
Celltrion27.8×2.4×8.9×—0.0%
Alteogen78.8×28.4×59.9×—0.1%
Yuhan24.8×2.5×2.6×32.5×0.8%
SK biopharmaceuticals14.6×5.7×6.8×—0.0%
HLB—15.4×54.6×—0.0%
Similar companies (median)27.8×6.7×11.5×32.5×0.0%

Calculated from end-of-day prices and filed financial statements. Not a recommendation. This is not financial advice.

Also known as: Samjin Pharmaceutical / 삼진제약 / 005500 / KRX:005500

Source: KRX statistical information